Telotristat Etiprate Patent Expiration

Telotristat Etiprate is used for treating carcinoid syndrome diarrhea in adults inadequately controlled by somatostatin analog therapy. It was first introduced by Tersera Therapeutics Llc in its drug Xermelo on Feb 28, 2017.


Telotristat Etiprate Patents

Given below is the list of patents protecting Telotristat Etiprate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xermelo US7709493 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use Feb 28, 2031 Tersera
Xermelo US8193204 Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use Feb 27, 2031 Tersera
Xermelo US8653094 Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Dec 19, 2028 Tersera
Xermelo US7553840 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use Dec 11, 2027 Tersera
Xermelo US7968559 Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Dec 11, 2027 Tersera



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Telotristat Etiprate's patents.

Given below is the list recent legal activities going on the following patents of Telotristat Etiprate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 22 Nov, 2023 US8193204
Payment of Maintenance Fee, 12th Year, Large Entity 14 Dec, 2022 US7968559
Mail Pub Notice re 312 amendment 01 Mar, 2022 US7709493
Email Notification 01 Mar, 2022 US7709493
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 25 Feb, 2022 US7709493
Post Issue Communication - Certificate of Correction Denied 25 Feb, 2022 US7709493
Patent Term Extension Certificate 06 Dec, 2021 US7709493
Change in Power of Attorney (May Include Associate POA) 27 Oct, 2021 US8193204
Email Notification 27 Oct, 2021 US8193204
Correspondence Address Change 25 Oct, 2021 US8193204


Telotristat Etiprate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List